CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 114 enrolled
Drug / intervention
minocycline +1 moredrug
Likely dose
minocycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00277355
NCT00277355Phase 3Completed
CompareCT.gov

A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease

Merit Cudkowicz·interventional·Posted Jan 16, 2006·Updated Apr 19, 2013

In Brief

A Phase 3 clinical trial evaluating minocycline and Matching placebo for Huntington Disease. Completed, enrolled 114 participants across 12 sites in 2 countries.

Detailed Summary

This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the change in Huntington's disease symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesCanada, United States
CollaboratorsFDA Office of Orphan Products Development

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2006
Enrollment StartApr 1, 2006
Primary CompletionOct 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.5 years ago

Interventions

minocyclinedrug

Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)

Matching placebodrug

Matching placebo 1 capsule twice daily, 18 months treatment duration.